Real‐world performance of a clinical droplet digital polymerase chain reaction assay for non‐invasive foetal blood group and platelet antigen genotyping of alloimmunized pregnant women with antibodies directed against RhD , RhE , Rhc, RhC , K1 , HPA ‐1a or HPA ‐5b: A 1‐year experience
Vox Sanguinis · 2025
DOI: 10.1111/vox.13777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2025. Verfasst von Camilla Calandrini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Laboratory Advise, Sanquin Diagnostic Services, Sanquin, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Antigens, Human Platelet, Isoantibodies, Blood Group Antigens, Polymerase Chain Reaction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Objectives To test the performance of a new droplet digital polymerase chain reaction (ddPCR) non‐invasive foetal blood group and platelet antigen genotyping assay in the setting of a Dutch reference laboratory for foetal blood group and platelet antigen genotyping. Our population comprised 229 consecutive alloimmunized pregnant women who presented between April 2022 and March 2023 with 250 requests for non‐invasive foetal RHD , RHE , RHc , RHC , K1 , HPA‐1a or HPA‐5b blood group and platelet antigen genotyping. Materials and Methods Samples were genotyped for blood group and platelet antigen alleles along with methylated RASSF1a ( mRASSF1a ) and sex‐determining region of Y ( SRY ) and DYS14 as positive foetal controls. Negative blood group and platelet antigen results were issued only when foetal controls were positive; otherwise, such samples were classified as inconclusive.
Results
The assay achieved a success rate of 98.4% (246 of 250) because one case was lost to follow‐up, one case was solved with quantitative polymerase chain reaction (qPCR) and one case precluded foetal typing due to RHD variant mothers. Only 10 cases needed a second sample and one case a third for a valid final result. We identified 116 maternal–foetal blood group and platelet antigen incompatibilities.
Conclusion
Clinical non‐invasive foetal blood group and platelet antigen typing of alloimmunized pregnant women via ddPCR is successful and represents an improvement over qPCR because of the addition of a foetal control and because ddPCR circumvents potential interference from maternal cell‐free DNA (cfDNA) background for foetal HPA‐1 and K1 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Laboratory Advise, Sanquin Diagnostic Services, Sanquin, Amsterdam, The Netherlands.
- Department of Immunohematology Diagnostics, Sanquin Diagnostic Services, Sanquin, Amsterdam, The Netherlands.
- Department of Immunocytology, Sanquin Diagnostic Services, Sanquin, Amsterdam, The Netherlands.
- Department of Experimental Immunohematology, Sanquin, Amsterdam, The Netherlands.
- Sanquin Blood Supply, Amsterdam, The Netherlands.
- Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Erik H van Beers, C Ellen van der Schoot, Masja de Haas
Zitieren
APA
Calandrini, C., Verhagen, O. J. H. M., Tissoudali, A., Homburg, C. H. E., Vessies, J., Brussee, M., van Beers, E. H., van der Schoot, C. E., & de Haas, M. (2025). Real‐world performance of a clinical droplet digital polymerase chain reaction assay for non‐invasive foetal blood group and platelet antigen genotyping of alloimmunized pregnant women with antibodies directed against RhD , RhE , Rhc, RhC , K1 , HPA ‐1a or HPA ‐5b: A 1‐year experience. Vox Sanguinis. https://doi.org/10.1111/vox.13777
Vancouver
Calandrini C, Verhagen OJHM, Tissoudali A, Homburg CHE, Vessies J, Brussee M, et al. Real‐world performance of a clinical droplet digital polymerase chain reaction assay for non‐invasive foetal blood group and platelet antigen genotyping of alloimmunized pregnant women with antibodies directed against RhD , RhE , Rhc, RhC , K1 , HPA ‐1a or HPA ‐5b: A 1‐year experience. Vox Sanguinis. 2025. doi:10.1111/vox.13777
BibTeX
@article{Calandrini2025,
author = {Calandrini, Camilla and Verhagen, Onno J H M and Tissoudali, Ahmed and Homburg, Christa H E and Vessies, Jessica and Brussee, Mark and van Beers, Erik H and van der Schoot, C Ellen and de Haas, Masja},
title = {Real‐world performance of a clinical droplet digital polymerase chain reaction assay for non‐invasive foetal blood group and platelet antigen genotyping of alloimmunized pregnant women with antibodies directed against RhD , RhE , Rhc, RhC , K1 , HPA ‐1a or HPA ‐5b: A 1‐year experience},
journal = {Vox Sanguinis},
year = {2025},
doi = {10.1111/vox.13777}
}
EUVIMED